What is ivabradine, including its mechanism of action, clinical indications, dosing regimen, contraindications, and common adverse effects?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

What is Ivabradine

Ivabradine is a selective heart rate-lowering medication that specifically inhibits the If (funny) current in the sinoatrial node, reducing heart rate without affecting blood pressure, myocardial contractility, or cardiac conduction. 1, 2, 3

Mechanism of Action

Ivabradine works by selectively blocking hyperpolarization-activated cyclic nucleotide-gated (HCN) channels that carry the If current in sinoatrial node pacemaker cells 1, 2. This inhibition:

  • Reduces the slope of slow diastolic depolarization in sinus node cells, thereby lowering heart rate
  • Acts in a "use-dependent" manner - greater heart rate reduction when baseline heart rate is high, less reduction when baseline heart rate is low
  • Has no negative inotropic or lusitropic effects - does not depress myocardial contractility or impair diastolic relaxation 1
  • Does not lower blood pressure unlike beta-blockers or calcium channel blockers 2

Clinical Indications

FDA-Approved Indication (Primary)

Heart Failure with Reduced Ejection Fraction (HFrEF): Ivabradine is indicated to reduce hospitalization risk in patients with 2, 4, 3:

  • Stable, symptomatic chronic heart failure (NYHA class II-III)
  • Left ventricular ejection fraction ≤35%
  • Sinus rhythm with resting heart rate ≥70 bpm
  • Already receiving guideline-directed medical therapy including beta-blocker at maximum tolerated dose (or contraindication to beta-blockers)
  • Recent heart failure hospitalization within the preceding 12 months

The 2021 ACC guidelines give this a Class IIa, Level of Evidence B-R recommendation 2.

Secondary Indication

Chronic Stable Angina: In patients with chronic stable angina in sinus rhythm with heart rate ≥70 bpm who cannot tolerate or whose symptoms are inadequately controlled with beta-blockers, at appropriate doses up to 7.5 mg twice daily 1. The antianginal efficacy is similar to other antianginal agents, and ivabradine provides additional benefits when combined with other antianginal drugs (except diltiazem and verapamil) 1.

Dosing Regimen

Starting Dose

  • Standard patients: 5 mg twice daily with food 2, 3
  • Vulnerable patients: 2.5 mg twice daily for those with:
    • History of conduction defects
    • Age ≥75 years
    • Patients in whom bradycardia could lead to hemodynamic compromise 2, 3

Dose Titration (After 2 Weeks)

  • Heart rate >60 bpm: Increase by 2.5 mg twice daily
  • Heart rate 50-60 bpm: Maintain current dose
  • Heart rate <50 bpm or symptomatic bradycardia: Decrease by 2.5 mg twice daily; discontinue if already on 2.5 mg twice daily 2, 3

Maximum Dose

7.5 mg twice daily 2, 1, 3

Critical point: Beta-blockers should be optimized to target doses FIRST before initiating ivabradine, as only 25% of patients in the SHIFT trial were on optimal beta-blocker doses 2, 4.

Contraindications

Ivabradine is absolutely contraindicated in 3:

  • Acute decompensated heart failure
  • Clinically significant hypotension
  • Sick sinus syndrome, sinoatrial block, or 3rd-degree AV block (unless functioning demand pacemaker present)
  • Clinically significant bradycardia
  • Severe hepatic impairment
  • Pacemaker dependence (heart rate maintained exclusively by pacemaker)
  • Concomitant use of strong CYP3A4 inhibitors (ketoconazole, clarithromycin, nefazodone, ritonavir, nelfinavir)
  • Chronic or persistent atrial fibrillation 1

Important caveat: A history of paroxysmal atrial fibrillation is NOT a contraindication - nearly 10% of SHIFT trial patients had paroxysmal AF, with requirement for sinus rhythm at least 40% of the time 2.

Common Adverse Effects

Most Frequent (≥1%)

  • Bradycardia: 6.0% per patient-year (2.7% symptomatic, 3.4% asymptomatic) vs 1.3% with placebo 2, 3
  • Visual phenomena (phosphenes): 5.4% of patients - mild, transitory, caused by If channels in retina; rarely lead to treatment withdrawal (<1%) 1
  • Atrial fibrillation: Increased absolute incidence by 0.7% (5.0% vs 3.9% with placebo) 1
  • Hypertension 3

Monitoring Requirements

  • Regularly monitor cardiac rhythm for atrial fibrillation development - discontinue if AF occurs 3
  • Monitor heart rate and symptoms of bradycardia during treatment 3
  • Avoid concomitant use with diltiazem or verapamil (increase ivabradine exposure and contribute to heart rate lowering) 1, 3

Important Drug Interactions

  • Strong CYP3A4 inhibitors: Contraindicated (increase ivabradine levels) 3
  • Diltiazem and verapamil: Should be avoided - contraindicated in angina patients, increase bradycardia risk 1
  • Other negative chronotropes (digoxin, amiodarone): Increase bradycardia risk, monitor closely 3

Special Populations

Pregnancy: May cause fetal toxicity - embryo-fetal toxicity and cardiac teratogenic effects observed in animal studies. Advise effective contraception in females of reproductive potential 3.

Lactation: Breastfeeding not recommended 3.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.